Advanced Biomed, a Taiwanese developer of microfluidic testing equipment for early cancer screening, lowered the proposed deal size for its upcoming IPO on Monday. In its latest filing, the company also replaced sole bookrunner Univest Securities with Craft...read more
Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer, withdrew its plans for an initial public offering on Monday, citing market conditions. It had filed to raise $13 million by offering 2.6 million shares at a...read more
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, withdrew its plans for an initial public offering on Monday. It originally filed in January 2024 and most recently planned to raise $6 million by...read more
Taiwanese diagnostics developer Advanced Biomed slashes deal size by 92% ahead of $9 million US IPO
Advanced Biomed, a Taiwanese developer of microfluidic testing equipment for early cancer screening, lowered the proposed deal size for its upcoming IPO on Monday. In its latest filing, the company also replaced sole bookrunner Univest Securities with Craft...read more
Canadian diagnostics developer Breathe BioMedical withdraws $13 million US IPO
Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer, withdrew its plans for an initial public offering on Monday, citing market conditions. It had filed to raise $13 million by offering 2.6 million shares at a...read more
Neurodegenerative disease biotech APRINOIA Therapeutics withdraws $6 million IPO
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, withdrew its plans for an initial public offering on Monday. It originally filed in January 2024 and most recently planned to raise $6 million by...read more